Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Industry
Pharmaceutical Preparations
Location
7946 IVanhoe Avenue, Suite 201, La Jolla, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Leisure Acquisition Corp. (to 6/30/2021)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 147 % +84.5%
Debt-to-equity 125 %
Operating Margin -672 % -16.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.47M shares +196%
Common Stock, Shares, Outstanding 8.15M shares +205%
Entity Public Float 4.6M USD -75.5%
Common Stock, Value, Issued 815 USD +205%
Weighted Average Number of Shares Outstanding, Basic 8.82M shares +288%
Weighted Average Number of Shares Outstanding, Diluted 8.82M shares +288%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.44M USD -52%
Research and Development Expense 5.87M USD -60.4%
General and Administrative Expense 5.23M USD -3.02%
Operating Income (Loss) -9.66M USD +43.9%
Nonoperating Income (Expense) -1.62M USD +36.4%
Earnings Per Share, Basic -2.4 USD/shares +96.6%
Earnings Per Share, Diluted -2.4 USD/shares +77.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.04M USD -72.8%
Other Assets, Current 64.4K USD
Assets, Current 2.46M USD -58%
Other Assets, Noncurrent 336K USD -33.2%
Assets 2.8M USD -56%
Accounts Payable, Current 482K USD -62.2%
Liabilities, Current 1.31M USD -48.1%
Other Liabilities, Noncurrent 26.4K USD -91.5%
Liabilities 1.32M USD -48.7%
Retained Earnings (Accumulated Deficit) -127M USD -9.78%
Stockholders' Equity Attributable to Parent 1.81M USD -56.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1.48M USD -61%
Liabilities and Equity 2.8M USD -56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.41M USD +5.5%
Net Cash Provided by (Used in) Financing Activities 5.69M USD +203%
Net Cash Provided by (Used in) Investing Activities 4.5K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 8.15M shares +205%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.28M USD
Deferred Tax Assets, Valuation Allowance 38.4M USD +6.58%
Deferred Tax Assets, Gross 38.4M USD +6.56%
Depreciation 0 USD
Operating Lease, Liability, Current 2.73K USD -92.3%
Deferred Tax Assets, Operating Loss Carryforwards 28.5M USD +6.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 1.69M USD +18%
Operating Lease, Payments 22.7K USD +18.9%
Additional Paid in Capital 128M USD +7.51%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5.93K USD +7.98%
Interest Expense 1.25M USD +83271%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%